ArticleCurrent infectious disease reports2010
Treatment of resistant enterococcal urinary tract infections.
Article in Current infectious disease reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 57 citations in OpenAlex.
- Antibiotic Outcomes of Enterococcal Urinary Tract Infections: A Retrospective Analysis from Saudi Arabia and Oman.Pathogens (Basel, Switzerland) · 2026Article
- Enterococcal Urinary Tract Infections: A Review of the Pathogenicity, Epidemiology, and Treatment.Antibiotics (Basel, Switzerland) · 2023Review
- Comparative metabolite profiling of four polyphenol rich Morus leaves extracts in relation to their antibiofilm activity against Enterococcus faecalis.Scientific reports · 2022Article
- The Role of Gram-Negative Bacteria in Urinary Tract Infections: Current Concepts and Therapeutic Options.Advances in experimental medicine and biology · 2021Review
- Establishment and characterization of silver-resistant Enterococcus faecalis.Folia microbiologica · 2020Article
- Article
- Effectiveness of Efflux Pump Inhibitors as Biofilm Disruptors and Resistance Breakers in Gram-Negative (ESKAPEE) Bacteria.Antibiotics (Basel, Switzerland) · 2019Review
- Parenterally administered vancomycin in 29 dogs and 7 cats (2003-2017).Journal of veterinary internal medicine · 2019Article
- Synergistic mechanism of AgJournal of nanobiotechnology · 2018Article
- A urine-dependent human urothelial organoid offers a potential alternative to rodent models of infection.Scientific reports · 2018Article
- Changes in the incidence and antimicrobial susceptibility of healthcare-associated infections in a New York hospital system, 2006-2012.Journal of preventive medicine and hygiene · 2017Article
- Antibiotic Resistance and Virulence Phenotypes of Recent Bacterial Strains Isolated from Urinary Tract Infections in Elderly Patients with Prostatic Disease.Pathogens (Basel, Switzerland) · 2017Article
- Microbial Biofilms in Urinary Tract Infections and Prostatitis: Etiology, Pathogenicity, and Combating strategies.Pathogens (Basel, Switzerland) · 2016Review
- Risk factors associated with fluoroquinolone-resistant enterococcal urinary tract infections in a tertiary care university hospital in north India.The Indian journal of medical research · 2016Article
- Correlation between biofilm formation and gelE, esp, and agg genes in Enterococcus spp. clinical isolates.Virulence · 2014Article
- Vancomycin resistance has no influence on outcomes of enterococcal bacteriuria.The Journal of hospital infection · 2013Article
- Enterococcus faecalis subverts and invades the host urothelium in patients with chronic urinary tract infection.PloS one · 2013Article
- Daptomycin for a complicated urinary tract infection with vancomycin-resistant Enterococcus faecium in a renal transplant recipient.Clinical kidney journal · 2012Article
- Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.Mayo Clinic proceedings · 2011Review
- Chemical synthesis of bacteriophage G4.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterococcus spp have emerged as important pathogens in urinary tract infection (UTI), especially in hospitalized patients. Resistance to multiple antibiotics, including vancomycin, has become common, particularly in infections involving Enterococcus faecium. The management of UTIs caused by Enterococcus spp has become challenging given the presence of underlying comorbidities in these patients and the limited therapeutic options available to treat multidrug-resistant (MDR) Enterococcus. Routine therapy for asymptomatic bacteriuria with MDR-Enterococcus is not recommended. Removal of indwelling urinary catheters should be considered. Appropriate antibiotic therapy selection should be guided by urine culture and susceptibility results. Data are limited on the treatment of UTIs caused by MDR-Enterococcus. Potential oral agents active against MDR-Enterococcus that may be considered for acute uncomplicated UTI include nitrofurantoin, fosfomycin, and fluoroquinolones. Potential parenteral agents for the treatment of pyelonephritis and complicated UTIs caused by MDR-Enterococcus include daptomycin, linezolid, and quinipristin-dalfopristin. Aminoglycosides or rifampin may be considered as adjunctive therapy in serious infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.